Singapore markets close in 7 hours

Ultragenyx Pharmaceutical Inc. (0LIF.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
35.22-1.36 (-3.73%)
At close: 06:03PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 3-15.88%
S&P500 52-week change 319.21%
52-week high 354.48
52-week low 30.00
50-day moving average 344.36
200-day moving average 342.97

Share statistics

Avg vol (3-month) 3300
Avg vol (10-day) 3293
Shares outstanding 550.58M
Implied shares outstanding 6N/A
Float 862.64M
% held by insiders 14.66%
% held by institutions 198.58%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023


Profit margin -178.91%
Operating margin (ttm)-167.00%

Management effectiveness

Return on assets (ttm)-31.95%
Return on equity (ttm)-178.60%

Income statement

Revenue (ttm)402.86M
Revenue per share (ttm)5.72
Quarterly revenue growth (yoy)21.20%
Gross profit (ttm)-370.78M
EBITDA -652.51M
Net income avi to common (ttm)-720.74M
Diluted EPS (ttm)-6.87
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)551.98M
Total cash per share (mrq)7.72
Total debt (mrq)25.73M
Total debt/equity (mrq)19.94%
Current ratio (mrq)2.87
Book value per share (mrq)1.81

Cash flow statement

Operating cash flow (ttm)-458.72M
Levered free cash flow (ttm)-391.29M